

Kui Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9404336/publications.pdf>

Version: 2024-02-01

9
papers

137
citations

1937685
4
h-index

1588992
8
g-index

9
all docs

9
docs citations

9
times ranked

259
citing authors

#	ARTICLE	IF	CITATIONS
1	GSTM1 and GSTT1 Polymorphisms, Cigarette Smoking, and Risk of Colon Cancer: A Population-based Case-control Study in North Carolina (United States). <i>Cancer Causes and Control</i> , 2006, 17, 385-394.	1.8	54
2	Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China. <i>Drug Safety</i> , 2018, 41, 125-137.	3.2	39
3	Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. <i>Familial Cancer</i> , 2011, 10, 303-308.	1.9	16
4	Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: A population-based retrospective cohort study. <i>Vaccine</i> , 2020, 38, 3422-3428.	3.8	13
5	Suitability of databases in the <scp>Asiaâ€Pacif</scp> for collaborative monitoring of vaccine safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 843-857.	1.9	5
6	Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A postâ€authorization safety cohort study conducted in Europe and in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 758-769.	1.9	4
7	The incidence of acute myocardial infarction after elective spinal fusions or joint replacement surgery in the United States: a large-scale retrospective observational cohort study in 322,585 patients. <i>Patient Safety in Surgery</i> , 2021, 15, 30.	2.3	3
8	The incidence of stroke among selected patients undergoing elective posterior lumbar fusion: a retrospective cohort study. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 612.	1.9	3
9	Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with nonâ€small cell lung cancer (NSCLC) in Europe. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00570.	2.4	0